Knowthestock.com
ACET - Adicet Bio Inc

Sell

Revenue was Negative

20%

based on last 5 year data.
Income Statement is WEAK
Revenue was Negative
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) turning Positive
Net Margin is -1010.9%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 9.1
Debt Ratio is 0.16
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Adicet Bio Inc (ACET) - www.adicetbio.com
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Exchange - NASDAQ/NMS (GLOBAL MARKET)
Industry - Medicinal and Botanical Manufacturing
Sector - Manufacturing
CEO -
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.